Article Details
Retrieved on: 2021-08-04 07:07:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
(CEO: Peter van de Sande, ”Synaffix”), a biotechnology company with a clinical-stage platform technology enabling best-in-class antibody-drug ...
Article found on: www.joplinglobe.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here